ClinicalTrials.gg
CompletedNCT03548714Updated Aug 22, 2019

Clinical Trial to Evaluate the Safety of PT150 (Formerly ORG34517) When it is Taken Concurrently With Alcohol

A Phase 1 interventional study of PT150 and Beverage in Alcohol Dependence and Alcohol Interaction, sponsored by Pop Test Oncology LLC. Completed at 1 site in United States. Open to participants aged 21 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-08-22.

Sponsored by Pop Test Oncology LLC · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2019, 7 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
21 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,074 studies in Alcoholism with a site in United States — 188 open to participants now, 228 under way, 15 of them phase 3. Alcoholism · United States.

Enrollment
897th of 990
10 · median 80
Started
2018
with 49 others
Phase 1
102 of 1,074
22 open now
Registered
604th of 1,074
by date

Among the 1,074 studies in Alcoholism with a site in United States, this one is the 897th largest by enrollment of the 990 interventional ones that give a count, is one of 50 that started in 2018, is one of 102 in phase 1, and was the 604th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

188 of the 1,074 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

183 more — sign in →

All 188 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,074 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

The purpose of the clinical study is to compare pharmacodynamic and safety endpoints following an alcohol challenge prior to and concurrent with PT150 (study drug) treatment.

Read the detailed description

This study can be classified as a phase 1, single center, and drug study. This within-subjects experimental procedure will assess the effects of PT150 (900 mg qd) on the subjective effects of alcohol in non-treatment-seeking alcohol-experienced volunteers (to include military service members, veterans and/or civilians). Study duration will be six days; in-house; Day 0 (admission) until day six (final study day and day of discharge). Participants will undergo two alcohol challenges on day 1 separated by 4 hours (one with alcohol, 0.8g/kg; 16% ethanol by volume, and one with placebo beverage, 1% ethanol by volume, randomly ordered) and receive active study drug (PT150) from days 1-5 (after alcohol challenge for day 1). On day 5, the study drug dosing will be followed by two more alcohol challenges (alcohol and placebo beverage randomly ordered). Physiologic (e.g., vital signs, electrocardiogram), subjective and psychometric effects (e.g., mood, urge, craving, stimulant and sedative effects), and breath alcohol levels (BAL) will be obtained after the alcohol challenges. On day six, an electrocardiogram (ECG) will be performed, adverse events (AEs) and symptom checklist will be collected, including symptoms of adrenal insufficiency (AI), and a blood draw for electrolyte levels and cortisol will be collected in the morning followed by breakfast and discharge if laboratory tests are within normal ranges. All serious adverse events will be followed clinically until resolved or clinically stable. Pharmacodynamic and safety endpoints will be assessed during the alcohol challenge prior to, and after 5 days of PT150 treatment, when PT150 has reached steady state. For females, a follow-up visit will be scheduled to occur at least 14 days after the final dose of PT150 is administered to ensure pregnancy does not occur. The objectives of the study are to compare pharmacodynamics and safety endpoints following an alcohol challenge prior to and concurrent with PT150. Given available pre-clinical and clinical evidence for the salutatory effect of glucocorticoid receptor (GR) antagonists on alcohol withdrawal, it was hypothesized that PT150 will not significantly alter pharmacodynamic measures and will be safe and well-tolerated under conditions of alcohol consumption.

03

Conditions studied

  • Alcohol Dependence
  • Alcohol Interaction

Keywords

  • Alcohol
  • Alcoholic
  • Alcoholism
  • Alcohol abuse
  • Alcohol interaction
  • Alcohol Use Disorder
  • Alcohol use
  • Alcohol dependence
  • Alcohol dependent
  • Ethanol abuse
  • Ethanol use
04

Who can participate

Ages eligible
21 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Provide signed and dated ;

  • male and female, ages 21 to 64;
  • must score \<10 on the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) assessed in the context of a blood alcohol level (BAL) ≤ 0.02% to demonstrate that they do not need medical detoxification; must have blood laboratory test results within acceptable limits (normal range as noted per protocol);
  • have normal vitals (heart rate 60-100 beats per minute (bpm), systolic blood pressure 90-140 millimeter of mercury (mmHg) and diastolic blood pressure 60-90 mmHg); a baseline (ECG) that demonstrates clinically normal sinus rhythm, clinically normal conduction, normal , and no arrhythmias;
  • have a self-reported medical history and brief physical examination demonstrating no clinically significant for study participation, in the judgement of the admitting physician;
  • must be willing to comply with all study procedures and be available for the duration of the study;
  • women must either be unable to conceive (i.e., surgically sterilized, sterile, or ) or using non-hormonal, medically acceptable during the study and for at least 2 weeks after study completion, with or without additional hormonal contraception Women can be receiving hormone replacement treatment (HRT) as long as the HRT dose has been stable for a period of at least 3 months;
  • women must provide negative urine pregnancy tests before study entry (urine), and before alcohol administrations on day 0 or 1 (serum) and on day 5 (urine);
  • able to provide proof of age and identity (includes providing full name and date of birth), forms of proof as defined per protocol.

Exclusion Criteria:

  • (DSM)-5 criteria for substance use disorders other than alcohol or nicotine or test positive for prescription or illegal substances. With regard to marijuana/tetrahydrocannabinols (THC), an individual must test negative at the baseline. If an individual tests positive they will be given a grace period where they will have the opportunity to return and test negative prior to being enrolled;
  • pregnant or nursing;
  • receiving HRT where their dose has not been stable for a minimum of 3 months;
  • use of concomitant medications (except birth control pills) or other the counter (OTC) supplements for at least 14 days or 5 half-lives (whichever is longer) before the start of the study and for the entire duration of the study. Concomitant medication use includes any prescription, OTC medications, or herbal supplements;
  • receiving any non-pharmacotherapy treatments or procedures for which there are precautions for taking concomitantly with PT150 and/or those that interfere with the study;
  • have neurological or psychiatric disorders other than Alcohol Use Disorder (AUD);
  • history of suicide attempts and/or current suicidal ideation/plan;
  • have evidence of untreated or unstable medical illness including: cardiovascular, neuroendocrine, , renal, hepatic, or active Human Immucodeficiency Virus () +, Acquired Immune Deficiency Syndrome (AIDS) infection;
  • have a history of medically adverse reactions to alcohol (e.g., loss of consciousness, chest pain, or epileptic seizure) or major alcohol-related medical complications requiring hospitalization (i.e., hepatitis or pancreatitis);
  • have contraindication(s) to take the study medications such as renal or hepatic impairment, congenital metabolic disorders, or to study medication class (i.e., glucosteroid abntagonist);
  • have past brain injury/head trauma with current symptoms (e.g., not photophobic, dizziness etc.) or past report of loss of consciousness (LOC) for >30 minutes and/or have been blast-exposed or had LOC >1 minute and current post-concussive symptoms;
  • self report more than thirty days' abstinence from alcohol during the three months prior to enrollment/consent;
  • current signs or violence or aggression, assessed as part of the consent process;
  • a history of adrenal insufficiency or a plasma cortisol level of ≤ 5 microgram per deciliter (mcg/dl) at screening or intake;
  • participation in a pharmaceutical trial or exposure to drugs within 1 month of the screening visit;
  • currently seeking treatment for AUD
  • have any other illness, condition, or use medication (psychotropic or antiretroviral), which in the opinion of the principal investigator (PI) and/or the admitting physician would preclude safe and/or successful completion of the study.
  • Have cortisol levels > 5 mcg/dl but \< 18 mcg/dL at baseline and an ACTH stimulation test that does not rule out adrenal insufficiency. Those with cortisol levels > 5 mcg/dl but \< 18 mcg/dL at baseline and cortisol levels ≥ 18 after stimulation testing can be enrolled.
  • Have been treated with any form of in the past 30 days.
  • Have a history of endometrial hyperplasia, endometrial cancer, uterine polyps, or unexplained vaginal bleeding.
  • Have uncontrolled hypertension (systolic blood pressure >140 mmHg and diastolic blood pressure >90 mmHg).
  • Have potassium levels below the normal reference range. Low serum potassium must be corrected prior to dosing in patients with abnormal baseline potassium levels.
  • Men taking testosterone replacement therapy.
  • Men or women currently interested in fertility.
  • Have underlying inflammatory or auto-immune disorders.
  • Have elevated thyroid stimulating hormone (TSH) levels.
  • Have diabetes.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    PT150 with alcohol consumption

    Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.

    Drug: PT150

  • Placebo comparator
    PT150 with placebo consumption

    Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.

    Other: Beverage

Interventions

  • DrugPT150

    Intervention 1 includes PT150 with alcohol consumption

    Also known as: Formerly ORG34517

  • OtherBeverage

    Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.

    Also known as: Placebo drink and ethanol drink

06

What researchers measure

Primary outcomes

  1. Change in Breath-alcohol levels (BALs) - Cmax

    Mean estimates of Cmax (observed maximum concentration after alcohol challenge) will be calculated and compared from post-alcohol challenge pre-treatment (day 1) to post alcohol challenge with concurrent treatment (day 5).

    Time frame: from post-alcohol challenge pre-treatment (day 1)to post alcohol with concurrent intreatment (day 5)

  2. Change in Breath-alcohol levels (BALs) - Tmax

    Mean estimates of Tmax (time of occurrence of Cmax) will be calculated and compared from post-alcohol challenge pre-treatment (day 1) to post alcohol challenge with concurrent treatment (day 5).

    Time frame: from post-alcohol challenge pre-treatment (day 1)to post alcohol with concurrent treatment (day 5)

  3. Change in Breath-alcohol levels (BALs) - AUC

    Mean estimates of AUC (area under the concentration curve through 2 hours post-alcohol challenge) will be calculated and compared from post-alcohol challenge pre-treatment (day 1) to post alcohol challenge with concurrent treatment (day 5).

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post alcohol with concurrent treatment (day 5)

  4. Change in blood pressure

    For each alcohol challenge on Days 1 and 5, the change in blood pressure (systolic and diastolic) is computed as the difference in blood pressure measurements taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  5. Change in Heart Rate (Pulse)

    For each alcohol challenge on days 1 and 5, the change in heart rate (pulse) is computed as the difference in heart rate measurements taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5).

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  6. Change in ECG abnormalities

    ECG abnormalities (normal, abnormal but not clinically significant, clinically significant abnormal) will be compared between pre-treatment (baseline, day 1 AM) to post-treatment (days 1 through 6)

    Time frame: from pre-treatment (baseline) to post-treatment (day 6)

  7. Change in Positive Affect score from the Positive and Negative Affect Schedule (PANAS)

    Positive changes in Positive Affect score indicate an increased positive affect. For each alcohol challenge on Days 1 and 5, the change in the positive affect scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  8. Change in Negative Affect score from the Positive and Negative Affect Schedule (PANAS)

    Negative changes in Negative Affect score indicate a decreased negative effect post-challenge. For each alcohol challenge on Days 1 and 5, the change in the negative affect scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  9. Change in Alcohol Urge Questionnaire (AUQ) score

    The change in AUQ score reflects the participant's thoughts and feelings about drinking, with negative score changes indicating a decrease in craving post-challenge. For each alcohol challenge on Days 1 and 5, the change in the AUQ scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  10. Change in Biphasic Alcohol Effects Scale (BAES) Sedative effects

    : The change in BAES sedative effects measures the sedative effects of alcohol, with a positive score change indicating an increase in sedation. For each alcohol challenge on Days 1 and 5, the change in the BAES sedative effects scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  11. Change in Biphasic Alcohol Effects Scale (BAES) Stimulant effects

    The change in BAES stimulant effects measures the stimulant effects of alcohol, with a positive score change indicating an increase in stimulation. For each alcohol challenge on Days 1 and 5, the change in the BAES stimulant effects scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  12. Change in Addiction Research Center Inventory (ARCI) score - Pentobarbital-Chlorpromazine-Alcohol Group Scale

    The Pentobarbital-Chlorpromazine-Alcohol Group (PCAG) Scale of the ARCI assesses the subjective effects of those psychologically active drugs, with positive score changes indicating an increase in sedation. For each alcohol challenge on Days 1 and 5, the change in the ARCI PCAG scale scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  13. Change in Addiction Research Center Inventory (ARCI) score - Amphetamine Scale

    The Amphetamine Scale of the ARCI assesses the subjective effects of that psychologically active drug, with positive score changes indicating an increase in stimulation. For each alcohol challenge on Days 1 and 5, the change in the ARCI amphetamine scale scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  14. Change in Addiction Research Center Inventory (ARCI) score - Morphine-Benzedrine Group (MBG) Scale

    The Morphine-Benzedrine Group Scale of the ARCI assesses the subjective effects of those psychologically active drugs, with positive score changes indicating an increase in euphoria/mood elevation. For each alcohol challenge on Days 1 and 5, the change in the ARCI MBG scale scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  15. Change in Addiction Research Center Inventory (ARCI) score - LSD Scale

    The LSD Scale of the ARCI assesses the subjective effects of that psychologically active drug, with positive score changes indicating an increase in dysphoric and psychotomimetic changes. For each alcohol challenge on Days 1 and 5, the change in the ARCI LSD scale scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  16. Change in Addiction Research Center Inventory (ARCI) score - Benzedrine Group Scale

    The Benzedrine Group Scale of the ARCI assesses the subjective effects of those psychologically active drugs, with positive score changes indicating an increase in intellectual efficiency and energy. For each alcohol challenge on Days 1 and 5, the change in the ARCI Benzedrine scale scores are computed as the difference in scores taken during the 2 hours after the alcohol challenges on days 1 and 5 and the ones collected immediately prior to that alcohol challenge. Mean changes are then calculated and compared from both post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

    Time frame: from post-alcohol challenge pre-treatment (day 1) to post-alcohol challenge with concurrent treatment (day 5)

  17. Differences in the adverse events

    Number of adverse events on day 1 (pre-treatment) will be compared to the number of adverse events on Day 5 (post-treatment). Proportion of patients experiencing an adverse event on day 1 (pre-treatment) may also be compared to the proportion of patients experiencing an adverse event on day 5 (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

Secondary outcomes

  1. Cognitive Assessment - Hopkins Verbal Learning Task-Revised (HLVT-R) Total Recall Score

    . Change in cognitive effects, measured by the HVLT-R Total Recall scores, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge day 5 (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  2. Cognitive Assessment - Hopkins Verbal Learning Task-Revised (HLVT-R) Delayed Recall Score

    . Change in cognitive effects, measured by the HVLT-R Delayed Recall scores, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge day 5 (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  3. Cognitive Assessment - Hopkins Verbal Learning Task-Revised (HLVT-R) Percent Retained Score

    . Change in cognitive effects, measured by the HVLT-R Percent Retained scores, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge day 5 (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  4. Cognitive Assessment - Hopkins Verbal Learning Task-Revised (HLVT-R) Discrimination Index Score

    . Change in cognitive effects, measured by the HVLT-R Discrimination Index scores, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge day 5 (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  5. Cognitive Assessment - Dual n-Back (DNB) auditory trial accuracy score

    Change in cognitive effects, measured by the DNB auditory trial accuracy scores, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  6. Cognitive Assessment - Dual n-Back (DNB) visual trial accuracy score

    Change in cognitive effects, measured by the DNB visual trial accuracy scores, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  7. Cognitive Assessment - Dual n-Back (DNB) auditory reaction time

    Change in cognitive effects, measured by the DNB auditory reaction times, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  8. Cognitive Assessment - Dual n-Back (DNB) visual reaction time

    Change in cognitive effects, measured by the DNB visual reaction time, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  9. Cognitive Assessment - Continuous Performance Task-2 (CPT) errors of commission score

    Change in cognitive effects, measured by the CPT errors of commission score, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  10. Cognitive Assessment - Continuous Performance Task-2 (CPT) errors of ommission score

    Change in cognitive effects, measured by the CPT errors of ommission score, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  11. Cognitive Assessment - Continuous Performance Task-2 (CPT) errors of perseveration score

    Change in cognitive effects, measured by the CPT errors of perseveration score, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  12. Cognitive Assessment - Continuous Performance Task-2 (CPT) reaction time

    Change in cognitive effects, measured by the CPT reaction time, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  13. Psychomotor Assessment - One Legged Stand (OLS)

    Change in psychomotor effects, measured by the OLS, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

  14. Psychomotor Assessment - Walk and Turn (WAT)

    Change in psychomotor effects, measured by the WAT, will be compared between the day 1 alcohol challenge (pre-treatment) and the day 5 alcohol challenge (post-treatment).

    Time frame: from pre-treatment (day 1) to post-treatment (day 5)

07

Study locations

1 site
  • Michael E. DeBakey Veterans Affairs Medical Center
    Houston, Texas 77030, United States
08

References and documents

Publications

  • Reynolds AR, Saunders MA, Brewton HW, Winchester SR, Elgumati IS, Prendergast MA. Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis activation. Drug Alcohol Depend. 2015 Sep 1;154:100-4. doi: 10.1016/j.drugalcdep.2015.06.018. Epub 2015 Jun 22. PubMed 26143299 ↗
  • Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, McGinn MA, Zamora-Martinez ER, Belanoff JK, Hunt HJ, Sanna PP, George O, Koob GF, Edwards S, Mason BJ. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015 Aug 3;125(8):3193-7. doi: 10.1172/JCI79828. Epub 2015 Jun 29. PubMed 26121746 ↗
  • Morice C, Baker DG, Patel MM, Nolen TL, Nowak K, Hirsch S, Kosten TR, Verrico CD. A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers. Sci Rep. 2021 May 10;11(1):9876. doi: 10.1038/s41598-021-88609-6. PubMed 33972573 ↗

Individual participant data

Plan to share: Yes — Data will be shared with a registry per the data sharing plans of the Consortium.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Jul 2019, 10 months.

Of 75 phase 1 interventional studies under Alcoholism, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2018
First posted
Jun 7, 2018
StartActual
Sep 1, 2018
Primary completionActual
Jul 15, 2019
CompletionActual
Jul 15, 2019
Last update
Aug 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03548714
Lead sponsor
Pop Test Oncology LLC
Collaborators
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, Congressionally Directed Medical Research Programs, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, University of California, San Diego
Responsible party
Sponsor
First posted
Jun 7, 2018
Start date
Sep 1, 2018
Primary completion
Jul 15, 2019
Completion
Jul 15, 2019
Last update
Aug 22, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Org-34517

Start the discussion